CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Bausch Health Americas, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Bausch Health Americas, Inc.
One Enterprise
Phone: 949-461-6000p:949-461-6000 Aliso Viejo, CA  92656  United States
This company ceased filing statements with the SEC on 10/27/2010.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Bausch Health Americas, Inc., formerly Valeant Pharmaceuticals International, is a specialty pharmaceutical company. The Company focuses on developing and commercializing products in specialty central nervous system (CNS) disorders. As of December 31, 2009, the Company’s products within its development pipeline included Staccato loxapine, Pimavanserin, BVF-018, Fipamezole and GDNF. In May 2009, the Company acquired the United States commercialization rights to Wellbutrin XL from The GlaxoSmithKline Group of Companies (GSK).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
---YesYesYes-

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
--YesYes-YesYes

Industries
SIC Code Description
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer J. MichaelPearson 50 2/1/2008 2/1/2008
President BhaskarChaudhuri 55 3/10/2009 3/10/2009
Chief Financial Officer, Executive Vice President Peter J.Blott 48 3/21/2007 3/21/2007
8 additional Officers and Directors records available in full report.

Business Names
Business Name
Aton Pharma, Inc.
bioskin GmbH
Biovail Corporation
37 additional Business Names available in full report.

General Information
Number of Employees: 3,100 (As of 12/31/2009)
Outstanding Shares: 75,921,797 (As of 7/30/2010)
Shareholders: 4,352
Stock Exchange: NYSE
Federal Tax Id: 330628076
Email Address: webmaster@icnpharm.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 23, 2024